The Fly | ENLV

Novel Mechanism of Action: Enlivex's Allocetra employs a unique approach by rebalancing the immune system's macrophages, offering a distinct and potentially more effective strategy for treating cytokine storms and acute inflammatory conditions.

Broad Therapeutic Potential: Allocetra is a versatile platform technology with demonstrated efficacy across multiple severe inflammatory diseases, including sepsis, COVID-19, and Graft-versus-Host Disease, addressing diverse and significant unmet medical needs.

Positive Clinical Trial Data: The company has reported promising results from Phase II clinical trials for Allocetra in both sepsis and severe COVID-19, indicating strong therapeutic potential and a favorable safety profile that de-risks future development.

Clinical Trial Outcomes Risk: Clinical trials are complex, costly, and may not demonstrate the necessary safety or efficacy, leading to program termination or significant delays.

Regulatory Approval Uncertainty: Even with positive trial results, obtaining regulatory approvals from bodies like the FDA or EMA is not guaranteed and can be a lengthy and unpredictable process.

Sufficiency of Funding Risk: Enlivex is a development-stage company and will require significant additional capital to complete clinical trials and commercialize any products, which may not be available on favorable terms or at all.

Clinical Trial Outcomes Risk: Clinical trials are complex, costly, and may not demonstrate the necessary safety or efficacy, leading to program termination or significant delays.

Regulatory Approval Uncertainty: Even with positive trial results, obtaining regulatory approvals from bodies like the FDA or EMA is not guaranteed and can be a lengthy and unpredictable process.